Press Release Details

Magenta Therapeutics Announces Pricing of Public Offering

May 1, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2019-- Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the pricing of its public offering of 4,250,000 shares of its common stock at a price to the public of $13.25 per share, for total gross proceeds of approximately $56.3 million. All shares of common stock will be offered by Magenta. In addition, the underwriters have a 30-day option to purchase from Magenta up to 637,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 6, 2019, subject to customary closing conditions.

J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

Important Information

A registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission (“SEC”). The offering of these shares will be made only by means of a prospectus. Copies of the prospectus can be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, telephone: 631-274-2806.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management, including but not limited to statements related to Magenta’s ability to complete the financing and its use of proceeds. These and other risks are discussed in Magenta’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K, filed on March 19, 2019, and its periodic reports on Form 10-Q and Form 8-K, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Source: Magenta Therapeutics, Inc.

Magenta Therapeutics:
Manisha Pai, Vice President, Communications & Investor Relations
617-510-9193
mpai@magentatx.com

Privacy Preference Center

Advertising

The NID and IDE cookies are set by DoubleClick (which is owned by Google) to help build a profile of your interests and show you relevant ads on other sites. The 1P_JAR cookie (from google.com) carries out information about how the end user uses the website and any advertising that the end user may have seen before visiting the said website.

NID, IDE, 1P_JAR

Analytics

Magenta TX uses these cookies to collect information about how visitors use our Site. We use the information to compile reports and to help us improve the Site. The cookies collect information in an anonymous form, including the number of visitors to the Site, where visitors have come to the Site from and the pages they visited. If you do not allow these cookies we will not be able to include your visit in our statistics. You can read the full Google Analytics privacy policy at: https://www.google.com/policies/privacy/.

_ga,_gat,_gid, _gali

Other

Functionality

The OGPC cookie enables the functionality of Google Maps. s_cc Adobe Site Catalyst cookie, determines whether cookies are enabled in the browser. The s_sq and s_vi, Adobe Site Catalyst cookie, stores information about the previous link clicked within the site as well as identify unique visitors, with an ID and timestamp.

OGPC, s_cc, s_sq, s_vi